Business Wire

TX-MARY-KAY

16.7.2020 14:02:04 CEST | Business Wire | Press release

Share
Mary Kay Inc. Expands Partnership with The Nature Conservancy to Protect Waterways Across the Globe

Last year, Mary Kay Inc ., an international leader in corporate and social responsibility, announced the company had partnered with The Nature Conservancy to protect Texas fisheries and the Gulf of Mexico . Today, Mary Kay is proud to announce they’ve expanded that partnership with The Nature Conservancy to impact waterways—and native species—the world over.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005038/en/

“All life on Earth began in and depends on our oceans,” said Deborah Gibbins, Chief Operating Officer at Mary Kay. “Water is the most valuable resource on our planet, and it’s essential that we do our part to protect it. When we began scaling our partnership with The Nature Conservancy last year, we focused on the waterways surrounding our home state of Texas. But we’re a global company, and we knew the need for support stretched far beyond the Gulf of Mexico. We’re thrilled to advance ecosystems and biodiversity conservation globally.”

Founded in 1951, The Nature Conservancy is the leading conservation organization, working around the world to protect ecologically important lands and waters for nature and people. The Conservancy’s practices are rooted in science and are driven by pragmatic solutions to the most pressing conservation threats at the largest scale.

The conservation programs are as vast and diverse as the ocean life they’re designed to protect. Beyond the Texas fisheries program, Mary Kay will also support The Nature Conservancy through the following programs:

  • Australia: In Northern Australia, Mary Kay will partner with indigenous communities to increase women’s role in conservation, including refining community-based healthy spatial development, working with government and non-government partners to scale up the adoption of conservation tools, and establishing a women’s camp at Fish River Station, a 445,000-acre property in the Northern Territory.
  • New Zealand: In New Zealand, Mary Kay and The Nature Conservancy will engage with indigenous people in sustainable aquaculture, including supporting the implementation of restorative activities in Auckland’s Hauraki Gulf to restore wild shellfish populations and launching a challenge fund to encourage greater philanthropic support for restoration of wildlife.
  • Mexico: In Mexico, Mary Kay and The Nature Conservancy will partner on the Monterrey Water Fund, which will enhance watersheds and support women in the area. These improvements include irrigation systems, a substrate study, and the diversification of plant production.
  • China: In China, Mary Kay and The Nature Conservancy will work to protect rural headwaters to secure clean drinking water for millions of people across the country. By 2021, the team will demonstrate five headwater production projects in Zhejiang, Fujian, Guangdong, and one other province.
  • General Ocean: The partnership will also mitigate plastic pollution in Indo-Pacific tuna fisheries. Together, they will work with leading plastic researchers to identify the fisheries that are the biggest contributors to ocean pollution so high-impact pilot programs and be put in place to mitigate pollution and clean up our seas.
  • Solomon Islands: In the Solomon Islands, the partnership will protect turtles through female-led ecotourism of the South Pacific Ocean. Mary Kay’s contribution will help create a viable, locally-run ecotourism venture in the Arnavon Islands that strengthens turtle conservation and provides equitable, sustainable financial returns to communities that are best positioned to protect endangered species.
  • Colombia: Through the Bogota Water Fund, the partnership will improve water security for millions of people in Colombia.
  • Canada: In Canada, Mary Kay and The Nature Conservancy will strengthen indigenous stewards by supporting current and future community leaders in traditional territories. This is an investment in a healthy future for these communities, their lands and waters for future generations.
  • Europe: In the UK and Germany, the partnership will work to protect biodiversity and marine resources as they introduce the native European oyster. In Spain, the partnership will work to create a water fund—the country currently faces some of the worst challenges in terms of water scarcity and water quality.

“We need healthy, diverse oceans for fishing, working and playing,” said Lily Verdone, Director of Freshwater and Marine at The Nature Conservancy. “But protecting oceans is about more than just protecting our planet: oceans add $1.5 trillion to the global economy each year. Mary Kay has long worked to impact change that will sustain the earth for generations to come, so they are a natural—and welcome—partner for The Nature Conservancy. We’d already seen such impactful change in Texas, and we’re thrilled to see what their contributions will help us accomplish in communities across the world.”

Mary Kay also sponsored EarthxOcean conference, a livestreaming event that brought experts, researchers and conservations together in a livestream to discuss topics such as the High Seas Initiative, coral reef restoration, ocean plastic solutions and sustainable fisheries.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 55 years ago with three goals: offer rewarding opportunities for women, manufacture irresistible products and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to researching the science behind beauty and to manufacturing cutting-edge skin care, color cosmetics and nutritional supplements. Through the Mary Kay FoundationSM , the company has awarded more than $78 million to cancer research and domestic violence shelters. Mary Kay Ash’s original vision continues to shine—one lipstick at a time.

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 79 countries and territories, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye